Article

New theories in the pathogenesis of menstrual migraine.

Division of General Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Current Pain and Headache Reports (Impact Factor: 2.26). 01/2009; 12(6):453-62. DOI: 10.1007/s11916-008-0077-3
Source: PubMed

ABSTRACT Hormonal and nonhormonal factors play a role in the pathophysiology of menstrual migraine, but estrogen withdrawal appears to be the most potent of these factors. It is postulated that estrogen withdrawal directly enhances excitability of trigeminal afferents, modulates the synthesis of neuropeptides, activates/deactivates specific neurotransmitter systems, and influences the function of microglia. These changes could activate and/or sensitize the trigeminal system and increase the likelihood of migraine headache during perimenstrual time periods. Three new theories are advanced in this article to explain the pathophysiology of menstrual migraine. Only through an understanding of the mechanisms involved in menstrual migraine can we gain insight into the management of this severe and debilitating form of migraine headache.

0 Followers
 · 
60 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund Die Migräne ist eine komplexe, invalidisierende Erkrankung, die überwiegend Frauen im reproduktiven Alter betrifft. Ziel bei betroffenen Frauen muss es sein, eine Verhütungsmethode zu finden, die weder mit einem erhöhten Insultrisiko assoziiert ist noch den Migräneverlauf negativ beeinflusst. Um dies zu erreichen, ist eine sorgfältige Anamnese zum Ausschluss weiterer kardiovaskulärer Risiken erforderlich. Kontrazeption mit Gestagenen Unter den hormonellen Methoden stehen die Gestagenmethoden an erster Stelle. Sie erhöhen das Risiko für einen Insult nicht. Für Desogestrel 75 μg gibt es zudem immer mehr Hinweise, dass es den Verlauf hormonabhängiger und -unabhängiger Migränen bei der Mehrzahl der Frauen positiv beeinflussen kann. Weitere Verfahren Kombinierte hormonelle Kontrazeptiva (KHK) sollten nur ausnahmsweise verordnet werden. Die Migräne mit Aura ist eine absolute Kontraindikation. Kupferfreisetzende Intrauterinpessare beeinflussen den Verlauf der Migräne nicht. Hormonentzugsmigränen unter KHK kann man mit dem Langzyklus positiv beeinflussen. Es bleibt aber unklar, was dies für das individuelle Risiko eines zerebralen Insults bedeutet. Daher sind Gestagene vorzuziehen.
    Gynäkologische Endokrinologie 09/2013; DOI:10.1007/s10304-012-0535-1
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To assess the efficacy and tolerability of eletriptan in treating migraine attacks occurring within the defined menstrual time period of 1 day before and 4 days after onset of menstruation (menses days -1 to +4) compared with attacks occurring during non-menstrual time periods (occurring outside of menses days -1 to +4). Migraine attacks during menses have been associated with longer duration, higher recurrence rates, greater treatment resistance, and greater functional disability than those not associated with menses. The efficacy of eletriptan in treating migraine attacks associated with menstruation vs those outside a defined menstrual period has not been evaluated. Data were pooled from 5 similarly designed, double-blind, randomized, placebo-controlled trials of eletriptan 20 mg/40 mg/80 mg. Two groups were defined for this analysis: women with a single index migraine beginning during the menstrual (group 1) and non-menstrual (group 2) time periods. End points of interest were headache response at 2 hours, migraine recurrence and sustained responses for nausea, photo/phonophobia, and function. Logistic regression was used to compare group 1 vs group 2 and each eletriptan dose (20, 40, or 80 mg) vs placebo. Adverse events were also assessed. Of 3217 subjects pooled from 5 studies, 2216 women were either in group 1 (n = 630) or group 2 (n = 1586). Rates of headache response at 2 hours were similar in group 1 vs group 2 (odds ratio [OR] = 1.11 [95% confidence interval (CI) 0.91, 1.36]; P = .2944). The rate of headache recurrence was significantly higher in group 1 vs group 2 (26.8% vs 18.6%; OR = 1.67 [95% CI 1.23, 2.26]; P < .001). The odds of achieving sustained nausea responses were significantly lower in group 1 than in group 2 (OR = 0.70 [95% CI 0.54, 0.92]; P = .0097). There was no significant difference between group 1 and group 2 in the odds of achieving a sustained photo/phonophobia and functional response (OR = 0.96 [95% CI 0.77, 1.20]; P = .7269 and OR = 1.14 [95% CI 0.87, 1.50]; P = .3425, respectively). Adverse events were comparable between group 1 and group 2. Two-hour headache outcome measures were similar in women treated with eletriptan both within and outside of the defined menstrual time period (menses days -1 to +4). The main treatment differences between the 2 groups occurred 2-24 hours post-treatment, with higher recurrence rates and lower sustained response rates for nausea in the group treated during the menstrual time period.
    Headache The Journal of Head and Face Pain 10/2013; 54(2). DOI:10.1111/head.12257 · 3.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Women disproportionately suffer from many deep tissue pain conditions. Experimental studies show that women have lower pain thresholds, higher pain ratings and less tolerance to a range of painful stimuli. Most clinical and epidemiological reports suggest female gonadal hormones modulate pain for some, but not all, conditions. Similarly, animal studies support greater nociceptive sensitivity in females in many deep tissue pain models. Gonadal hormones modulate responses in primary afferents, dorsal horn neurons and supraspinal sites, but the direction of modulation is variable. This review will examine sex differences in deep tissue pain in humans and animals focusing on the role of gonadal hormones (mainly estradiol) as an underlying component of the modulation of pain sensitivity.
    Frontiers in Neuroendocrinology 07/2013; DOI:10.1016/j.yfrne.2013.07.002 · 7.58 Impact Factor